AGP Executive Report
Last update: 2 hours agoBiotech Update: Valneva reported Q1 2026 results and corporate guidance, with €30.9M total revenue (about €30.5M in product sales) and a shrinking operating cash burn to €0.3M, plus a note that Pfizer is expected to file regulatory submissions for its Lyme disease vaccine candidate. Cardiology Watch: Robocath says it has finished enrollment in a first-in-human robotic PCI study (20 patients) at a French center, reporting no safety concerns so far and promising technical outcomes across lesion types. Public Health Alerts: France is entering a heightened mosquito season after a record 2025 for local chikungunya transmission, with officials urging vigilance as tiger mosquitoes drive spread. Food Safety: Eastern Iowa inspectors cited multiple restaurants for issues like improper meat storage, temperature problems, and leaks into uncovered food.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
